PYRIMETHAMINE

| Trade Name | Daraprim (GlaxoSmithKlyne) |
|---------------------|--|
| Class | Antiparasitic/antimalarial agent |
| Mechanism of Action | Inhibits parasitic dihydrofolate reductase resulting in inhibition of tetrahydrofolic acid synthesis |
| Indications | Congenital toxoplasmosis (Used in combination with sulfadiazine) |
| Contraindications | Known megaloblastic anaemia |
| Supplied As | Pyrimethamine suspension 1mg/mL (prepared by pharmacy) |
| Dilution | None required |
| Dosage | 1mg/kg/dose If the patient has difficulty tolerating pyrimathamine give each dose with a feed to reduce the incidence of vomiting |
| Interval | Load: 1 mg/kg 12 hourly for 2 days then |
| | Maintenance: 1 mg /kg once a day for 6 months, then 1 mg/kg THREE times a week for a further 6 months. |
| Administration | Oral |
| Compatible With | N/A |
| Incompatible With | N/A |
| Interactions | Pyrimethamine reduces the anti-epileptic effect of phenytoin |
| | Antifolate effects are increased when pyrimethamine is given in combination with sulphonamides, trimethoprim, zidovudine or methotrexate. |
| | Folic Acid may reduce the anti-parasitic effect of pyrimethamine and also increase the risk of pyrimethamine induced bone marrow suppression, for these reasons folinic acid is used to counteract the antifolate effect of pyrimethamine. |
| | Avoid brands of sunblock that contain PABA as this may reduce the effectiveness of sulfadiazine. |
| Monitoring | Full blood count |
| Stability | 30 days at 2 – 8 °C |
| Storage | In the fridge |

| Adverse Reactions | Skin rash (including Stevens Johnson Syndrome), nausea, vomiting, diarrhoea, blood dyscrasias, raised AST, sensory neuropathy |
|-------------------|--|
| Metabolism | 15-40% metabolised by liver, approx 60% of dose excreted as unchanged drug by kidneys. |
| Comments | Folinic Acid (also known as Calcium Folinate or Leucovorin Calcium) is given three times a week to counteract the antifolate effects of pyrimethamine and sulfadiazine. |
| | Pyrimethamine is a section 29 medication and is not registered in NZ. Funded by Special Authority application SA1328 |
| References | Micromedex Paediatric Dosage Handbook 6th Ed 1999-2000 BNF for Children www.uptodate.com NZ formulary for children www.nzf.org.nz |
| Updated By | A Lynn, B Robertshawe December 2008 A Lynn, B Robertshawe Dec 2012 (re-order profile) A Lynn, B Robertshawe February 2022 (updated dosing as per a NZFc and Special Authority form number added) |